Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIALODINE vs EUTHROID-0.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRIALODINE is a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that potentiates the effects of serotonin, norepinephrine, and dopamine by blocking their reuptake at presynaptic neurons.
Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Neuropathic pain (off-label)
Replacement therapy in hypothyroidism (primary, secondary, tertiary),Suppression of TSH in thyroid cancer (off-label),Treatment of euthyroid goiter (off-label)
50–100 mg orally twice daily; maximum 200 mg/day.
Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.
Terminal elimination half-life is 6-8 hours in healthy adults; prolongs to 12-15 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal and hepatic function; clinically, steady-state is reached within 24-36 hours, and dosing interval adjustments may be needed in renal or hepatic impairment.
Primarily hepatic via CYP3A4 and CYP2D6 isoenzymes; active metabolite TRIALODINE-M1 contributes to therapeutic effect.
Levothyroxine (T4) is deiodinated to liothyronine (T3) primarily by type 1 and type 2 deiodinases in liver, kidney, and other tissues. T3 and T4 are also metabolized via glucuronidation and sulfation. Hepatic enzymes: UGT1A1, UGT1A3, SULT1A1.
Renal excretion accounts for 70-80% of clearance, primarily as unchanged drug. Biliary/fecal elimination constitutes 15-20%, with the remainder as minor metabolites.
Renal (approx. 20-40% as unchanged drug, primarily via glomerular filtration and tubular secretion); biliary/fecal (approx. 60-80% as metabolites and unchanged drug, with enterohepatic recirculation).
92-95% bound, primarily to alpha-1-acid glycoprotein and albumin.
Approximately 99% bound to serum proteins, primarily thyroxine-binding globulin (TBG), with lesser binding to transthyretin and albumin.
1.5-2.5 L/kg, indicating extensive tissue distribution.
Apparent volume of distribution is approximately 0.10-0.15 L/kg, indicating distribution primarily into extracellular fluid and highly protein-bound; small Vd reflects minimal tissue binding under steady-state conditions.
Oral: 60-70% due to first-pass metabolism; rectal: 80-90%; intravenous: 100%.
Oral bioavailability: 100% (tablets), as EUTHROID-0.5 is a combination product with synthetic T4 (levothyroxine) and T3 (liothyronine); T4 absorption is ~80% (fasting, taken with water), while T3 is nearly completely absorbed; overall bioavailability considered complete when taken as directed.
GFR ≥60 m L/min: no adjustment. GFR 30–59: 50 mg once daily. GFR 15–29: 25 mg once daily. GFR <15: contraindicated.
No dose adjustment required for GFR >30 m L/min; for GFR <30 m L/min, consider reducing dose by 25-50% and monitor TSH.
Child-Pugh A: no adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50% and monitor TSH.
1–2 mg/kg/dose orally twice daily; maximum 4 mg/kg/day (up to 200 mg/day).
Oral: 0.5-1 grain (30-60 mg) per 70 kg body weight once daily; for children <70 kg, use 0.5 grains (30 mg) once daily adjusted to TSH levels.
Initiate at 25 mg once daily; titrate slowly to a maximum of 100 mg/day. Monitor renal function and serum drug levels.
Initiate at 0.5 grains (30 mg) orally once daily; titrate slowly with 0.5 grain increments every 4-6 weeks; monitor for tachyarrhythmias and osteoporosis.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
No FDA boxed warning.
May cause serotonin syndrome when used with other serotonergic drugs.,Monitor for increases in blood pressure and heart rate.,Avoid abrupt discontinuation; taper dose to reduce withdrawal symptoms.,Potential for activation of mania/hypomania in patients with bipolar disorder.
Cardiovascular effects: angina, arrhythmias, heart failure. Thyrotoxicosis: excessive doses may cause symptoms of hyperthyroidism. Bone mineral density reduction with long-term overreplacement. Adrenal insufficiency: may precipitate crisis in untreated patients. Diabetes: insulin/oral hypoglycemic requirements may increase. Myxedema coma: rapid correction can be fatal.
Concomitant use with MAOIs or within 14 days of MAOI therapy.,Uncontrolled narrow-angle glaucoma.,Hypersensitivity to TRIALODINE or any excipients.
Hypersensitivity to active ingredients or excipients. Untreated adrenal insufficiency. Thyrotoxicosis (hyperthyroidism). Acute myocardial infarction. Uncontrolled cardiovascular disease.
Avoid grapefruit and grapefruit juice as they may increase TRIALODINE levels by inhibiting CYP3A4. High-fat meals may delay absorption; take consistently with or without food. Avoid alcohol.
Avoid taking with high-fiber foods, soy, or calcium supplements; separate by at least 4 hours.
First trimester: Limited human data; animal studies at 10x MRHD show skeletal anomalies (rib fusion, vertebral malformations). Second trimester: No specific pattern identified but risk of fetal growth restriction. Third trimester: May cause premature closure of ductus arteriosus (risk of persistent pulmonary hypertension) and oligohydramnios due to fetal renal effects.
EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoid, as untreated hypothyroidism is linked to congenital anomalies and neurodevelopmental deficits. No evidence of fetal harm from levothyroxine at therapeutic doses. Second and third trimester: transfers minimal amounts across placenta, but adequate maternal levels are essential for fetal neurodevelopment. Risk of fetal goiter if mother is overtreated (TSH suppression).
Excreted in human milk (M/P ratio 1.2). Peak milk concentration 2 hours post-dose. Relative infant dose 8% of maternal weight-adjusted dose. Avoid breastfeeding due to potential for infant hypotension and renal impairment.
Levothyroxine is excreted into breast milk in minimal amounts, but no adverse effects in nursing infants have been reported. The milk-to-plasma (M/P) ratio is approximately 0.5 (range 0.4-0.6). Breastfeeding is considered safe while on levothyroxine therapy. Monitor infant thyroid function if high doses are used.
Clearance increases by 40% in second trimester and 50% in third trimester. Starting dose may need to be titrated upward (e.g., 1.5-fold increase) to maintain therapeutic effect. Monitor drug levels with target trough concentration 5-10 mcg/m L.
Pregnancy increases levothyroxine requirements in many women with hypothyroidism. Dose often increases by 30-50% starting at 4-6 weeks gestation. Monitor TSH and free T4 every 4-6 weeks and adjust dose accordingly to maintain euthyroid state. Postpartum, dose usually returns to prepregnancy levels.
TRIALODINE is a synthetic opioid analgesic; monitor for respiratory depression especially in opioid-naïve patients and those with COPD. Due to its long half-life (24-48 hours), dose titration should be gradual. Avoid in patients with paralytic ileus or suspected surgical abdomen. Contraindicated in patients with known hypersensitivity to triazoline opioids. In renal impairment (Cr Cl <30 m L/min), reduce dose by 50%.
Euthroid-0.5 contains liothyronine (T3). Monitor for signs of thyrotoxicosis due to rapid onset. T3 has a shorter half-life than levothyroxine; consider twice-daily dosing. Use with caution in elderly and patients with cardiac disease.
Do not crush or chew extended-release tablets; swallow whole.,Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines) due to risk of severe sedation and respiratory depression.,Do not stop abruptly; withdrawal symptoms (e.g., anxiety, sweating, diarrhea) may occur.,Store in a secure place out of reach of children; do not share medication.,May cause constipation; increase fluid and fiber intake, and consider stool softeners if needed.,Report dizziness, slow heart rate, or difficulty breathing immediately.,Do not drive or operate machinery until you know how TRIALODINE affects you.
Take exactly as prescribed, usually once daily.,Do not stop abruptly without consulting your doctor.,Report symptoms of hyperthyroidism: palpitations, tremor, anxiety, heat intolerance.,Store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIALODINE vs EUTHROID-0.5, answered by our medical review team.
TRIALODINE is a Thyroid Hormone that works by TRIALODINE is a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that potentiates the effects of serotonin, norepinephrine, and dopamine by blocking their reuptake at presynaptic neurons.. EUTHROID-0.5 is a Thyroid Hormone Replacement that works by Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIALODINE and EUTHROID-0.5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIALODINE is: 50–100 mg orally twice daily; maximum 200 mg/day.. The standard adult dose of EUTHROID-0.5 is: Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIALODINE and EUTHROID-0.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIALODINE is classified as Category C. First trimester: Limited human data; animal studies at 10x MRHD show skeletal anomalies (rib fusion, vertebral malformations). Second trimester: No specific pattern identified but . EUTHROID-0.5 is classified as Category C. EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.